Beam Therapeutics Propriété du management
Quel est le Propriété du management de Beam Therapeutics?
Le Propriété du management de Beam Therapeutics Inc. est 1.90%
Quelle est la définition de Propriété du management?
La propriété d'un initié est calculée en divisant le nombre total d'actions possédées par des initiés (actionnaires détenant plus de 5% de la société ou un dirigeant ou un administrateur de la société) par le nombre total d'actions en circulation.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Propriété du management des entreprises dans Health Care secteur sur NASDAQ par rapport à Beam Therapeutics
Que fait Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Entreprises avec propriété du management similaire à Beam Therapeutics
- Five Below Inc a Propriété du management de 1.89%
- Charter Hall Retail Real Estate Investment Trust a Propriété du management de 1.89%
- Coherent Corp a Propriété du management de 1.89%
- Oxford Immunotec Global PLC a Propriété du management de 1.89%
- Silver Lake Resources a Propriété du management de 1.90%
- CryoPort Inc a Propriété du management de 1.90%
- Beam Therapeutics a Propriété du management de 1.90%
- Murata Manufacturing Co a Propriété du management de 1.90%
- Vista Outdoor Inc a Propriété du management de 1.90%
- Timbercreek a Propriété du management de 1.90%
- iRobot a Propriété du management de 1.90%
- Cincinnati a Propriété du management de 1.90%
- AMBAC a Propriété du management de 1.91%